Tables
- TABLE 1
Characteristics of patients who started monitoring in the different study arms
Characteristics at GP consultation Study arm Dexamethasone Control group Subjects, n 4 2 Male sex 3 (75) 2 (100) Age group <65 years 2 (50) 1 (50) ≥65 years 2 (50) 1 (50) Obesity (BMI ≥30 kg·m−2) 2 (50) 0 (0) Asthma 2 (50) 0 (0) COPD 1 (25) 0 (0) Cardiovascular disease 1 (25) 1 (50) Diabetes mellitus 1 (25) 1 (50) Dyspnoea degree None or mild 2 (50) 0 (0) Moderate 1 (25) 2 (100) Severe 1 (25) 0 (0) Temperature ≥38.0°C 2 (50) 0 (0) SpO2 at rest#, % 99/97/94/93 94/92 SpO2 after STS#, % 95/92/90/89 88/91 Outcome Time to recovery, days#,¶ >28/>28/NA/NA 14/8 Severe COVID-19# Yes/No/Yes/Yes No/No Data are presented as n (%), unless otherwise stated. BMI: body mass index; SpO2: peripheral oxygen saturation; STS: sit-to-stand test; NA: not available due to hospital admission. #: individual values; ¶: defined as self-reported recovery for at least 2 consecutive days.
Vol 8 Issue 2
Table of Contents
A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study
